Company |
Type of |
Number of |
Amount |
Investors; placement agents; details
|
Date |
TOTAL: $343.37M | |||||
Agenus Inc. (Lexington, Mass.) |
Royalty transaction |
N/A |
$100 |
Agenus conducted a $115M royalty transaction relating to a note purchase agreement with an investor group led by Oberland Capital Management LLC; it is receiving $100M at closing and $15M upon FDA approval of HZ/su no later than June 30, 2018; the royalties are for Glaxosmithkline plc's shingles and malaria prophylactic vaccine products that contain QS-21 adjuvant until all principal and interest are paid |
9/10/15 |
Akari Therapeutics plc (New York) |
Private placement |
N/A |
$75 |
Akari raised $75M in a private placement led by Deerfield, and including Venrock, Vivo Capital, Foresite Capital, New Enterprise Associates, QVT Financial, RA Capital Management and certain other institutional investors |
9/22/15 |
Aytu Bioscience Inc. (Englewood, Colo.) |
Private placement convertible note financing |
N/A |
$5.1 |
Aytu closed the final tranche of its planned private placement convertible note financing, raising $5.1M, which includes proceeds from two prior tranches; Newbridge Securities Corp., through Lifetech Capital, acted as sole placement agent |
9/3/15 |
Biotime Inc. (Alameda, Calif.) |
Registered direct offering |
N/A |
$20.7 |
Biotime will sell up to $20.7M of its common shares in a registered direct offering to select investment funds in Israel |
9/29/15 |
Can-Fite Biopharma Ltd. (Petach Tikva, Israel) |
Registered direct offering |
2.069ADS |
$9 |
Can-Fite received $9M by issuing 2.069M registered American Depositary Shares at $4.35 per ADS |
9/22/15 |
Casi Pharmaceuticals Inc. (Rockville, Md.) |
Private placement |
20.65S and 4.13W |
$25 |
Casi raised $25.1M in a financing led by a China investment fund manager affiliated with the same management team of its largest shareholder, IDG-Accel China Growth Fund III LP; the financing includes 20.65M shares of common stock at $1.19 each and a total of 4.13M warrants with a purchase price of $0.125 per whole warrant share |
9/22/15 |
Cellectar Biosciences Inc. (Madison, Wis.) |
Registered direct offering |
1.01S and W for 0.482728S |
$5.52 |
Cellectar priced an offering of 1.01M shares of common stock and series B pre-funded warrants to purchase 482,728 shares of common stock at $2.20 per share, to raise $2.22M; it conducted a private placement issuing series A warrants to purchase 1.5M shares at $2.83 each, raising $3.3M |
9/29/15 |
Cesca Therapeutics Inc. (Rancho Cordova, Calif.) |
Senior secured convertible debentures and warrants placement |
N/A |
$15 |
Cesca reported the signing and initial closing of a definitive agreement to raise $15M from one institutional investor |
9/2/15 |
Cortex Pharmaceuticals Inc. (Glen Rock, N.J.) |
Private placement |
34.3U |
$0.72 |
Cortex closed $721,180 in financing from a private placement of 34.3M units, consisting of one common stock and one warrant to purchase two additional shares of common stock priced at $0.02103 per share |
9/1/15 |
CTI Biopharma Corp. (Seattle) |
Registered direct offering |
10S |
$15.7 |
CTI raised $15.7M in a registered direct offering |
9/28/15 |
Invion Ltd. (Brisbane, Australia) |
Private placement |
71.5S |
$0.7 |
Invion issued 71.5M fully paid ordinary shares at A1.4 cents per share in a private placement to a U.S. institutional investor for aggregate gross proceeds of A$1.001M (US$703,044) |
9/2/15 |
Medifocus Inc. (Toronto) |
Private placement |
500U |
$5 |
Medifocus raised $5M in a private placement of up to 500 units at $10,000 per unit; each unit is comprised of 200,000 common shares of the company, and 100,000 series F common share purchase warrants |
9/30/15 |
Opexa Therapeutics Inc. (The Woodlands, Texas) |
Private placement |
N/A |
$1 |
Opexa entered a stock purchase agreement with a private investor for up to $5M in five tranches; the first tranche brought in $500,000 |
9/2/15 |
Orexigen Therapeutics Inc. (San Diego) |
Private placement |
20S and W for 5S |
$60 |
Orexigen raised $60M through the placement of 20M shares and warrants to purchase 5M shares with funds managed by the Baupost Group LLC |
9/11/15 |
Sirona Biochem Corp. (Vancouver, British Columbia) |
Warrant exercise |
6.42S |
$1 |
Sirona generated $1.024M as a result of share purchase warrant exercises of 6.12M shares and the share purchase option exercise of 300,000 shares |
9/30/15 |
Therapy Cells Inc. (Venice, Fla.) |
Investment |
N/A |
$2.7 |
Therapy Cells received $2.7M in funding from Sofinnova Partners, which exercised its option to advance the development of its cell process; if all contract options are exercised, Therapy Cells will receive a total award of up to $5.7M |
9/24/15 |
Uluru Inc. (Addison, Texas) |
Private placement |
4.1S |
$1.6 |
Uluru raised $1.6M by placing 4.1M shares at 38 cents each to a group of European investors |
9/14/15 |
|
Notes This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed. Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. N/A = Not applicable; ND = Not disclosed. This chart includes only biotech companies that develop therapeutics. | |||||
